投資有価証券評価損、資本剰余金(IFRS)、外部収益 - 医薬
- 【期間】
年度 | 投資有価証券評価損 | 資本剰余金(IFRS) | 外部収益 - 医薬 |
---|
2008/12 | - | | - | | - | |
2009/12 | - | | - | | - | |
2010/12 | - | | - | | - | |
2011/03 | - | | - | | - | |
2011/06 | -66億 | | - | | - | |
2011/09 | 223億 | 黒転 | - | | - | |
2011/12 | - | | - | | - | |
2012/03 | - | | - | | - | |
2012/06 | - | | - | | - | |
2012/09 | - | | - | | - | |
2012/12 | - | | - | | - | |
2013/03 | - | | - | | - | |
2013/06 | - | | - | | - | |
2013/09 | - | | - | | - | |
2013/12 | - | | - | | - | |
2014/03 | - | | - | | - | |
2014/06 | - | | - | | - | |
2014/09 | - | | - | | - | |
2014/12 | - | | - | | - | |
2015/12 | - | | - | | - | |
2016/06 | - | | - | | - | |
2016/09 | - | | - | | - | |
2016/12 | - | | - | | - | |
2017/03 | - | | - | | - | |
2017/06 | - | | - | | - | |
2017/09 | - | | - | | - | |
2017/12 | - | | - | | - | |
2018/12 | - | | 22.4億 | | 2704億 | |
2019/03 | - | | - | | 756億 | -72.1% |
2019/06 | - | | - | | 1509億 | +99.7% |
2019/09 | - | | - | | 2247億 | +48.9% |
2019/12 | - | | 249億 | 大幅増 | 3049億 | +35.7% |
2020/03 | - | | 249億 | +0% | 772億 | -74.7% |
2020/06 | - | | 249億 | +0% | 1575億 | +104.2% |
2020/09 | - | | 249億 | +0.2% | 2336億 | +48.3% |
2020/12 | - | | 249億 | +0.1% | 3178億 | +36% |
2021/03 | - | | 250億 | +0.2% | 810億 | -74.5% |
2021/06 | - | | 250億 | -0% | 1647億 | +103.5% |
2021/09 | - | | 251億 | +0.3% | 2536億 | +53.9% |
2021/12 | - | | 251億 | +0.1% | 3517億 | +38.7% |
2022/03 | - | | 252億 | +0.4% | 876億 | -75.1% |
2022/06 | - | | 253億 | +0.3% | 1850億 | +111.2% |
2022/09 | - | | 254億 | +0.4% | 2834億 | +53.2% |
2022/12 | - | | 255億 | +0.6% | 3979億 | +40.4% |
2023/03 | - | | 209億 | -18.1% | 934億 | -76.5% |
2023/06 | - | | 209億 | +0.1% | 1990億 | +113% |
2023/09 | - | | 210億 | +0.6% | 3058億 | +53.7% |
2023/12 | - | | 212億 | +0.5% | 4419億 | +44.5% |
2024/03 | - | | 191億 | -9.9% | 1055億 | -76.1% |
2024/06 | - | | 133億 | -30.4% | 2328億 | +120.7% |